SuperCom (NASDAQ:SPCB) reported quarterly losses of $(0.01) per share which beat the analyst consensus estimate of $(0.10) by 90 percent. The company reported quarterly sales of $3.00 million which missed the analyst consensus estimate of $3.20 million by 6.25 percent.
SVB Leerink Maintains Outperform on F-star Therapeutics, Lowers Price Target to $21
SVB Leerink analyst Daina Graybosch maintains F-star Therapeutics (NASDAQ:FSTX) with a Outperform and lowers the price target from $25 to $21.